Veronica Galvan, Ph.D.
Dr. Veronica Galvan’s research focuses on the identification of molecular and biochemical alterations that cause Alzheimer’s disease and other dementias. She has generated novel experimental models of Alzheimer's and used them to identify mechanisms of neurodegeneration in this disease. After joining the faculty at the University of Texas Health San Antonio in 2009 Dr. Galvan pioneered the study of mechanisms that link the mechanisms that control brain aging to the pathogenesis of Alzheimer’s and other dementias. Her laboratory provided the first demonstration of a role of the target of rapamycin (TOR), a central regulator of mammalian aging, in the initiation of Alzheimer's and vascular cognitive impairment-like disease in surrogate models. Dr. Galvan’s group also recently reported, for the first time, the accumulation of pathological forms of tau protein in brain microvasculature in Alzheimer's and other tauopathies. Major goals of the Galvan Lab are to define how TOR links brain aging to the initiation and progression of Alzheimer’s disease and other dementias and understand how the accumulation of misfolded forms of tau in brain vasculature drive cerebrovascular and cognitive dysfunction in neurodegenerative disease.